Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST II: Zoledronic Acid for Fracture Prevention
NCT02589600Phase 4Completed
- Start
- Jan 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zoledronic acid in osteoporosis (2 arms). Primary endpoint: Non-traumatic Incidental Fractures (Vertebral and Nonvertebral) at 3 years. Started Jan 2016; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02589600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589600.